{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:38:34Z","timestamp":1786804714457,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.11.002","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T05:28:01Z","timestamp":1604986081000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting"],"prefix":"10.1016","volume":"54","author":[{"given":"M.","family":"Clemons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dranitsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sehdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.breast.2020.11.002_bib1","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.breast.2020.11.002_bib2","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.breast.2020.11.002_bib3","series-title":"Clinical evidence for recommendations","author":"War","year":"2013"},{"issue":"8","key":"10.1016\/j.breast.2020.11.002_bib6","first-page":"374","article-title":"Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study","volume":"5","author":"Booth","year":"2007","journal-title":"J\u00a0Support Oncol"},{"issue":"6","key":"10.1016\/j.breast.2020.11.002_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"Ng","year":"2015","journal-title":"Oncol"},{"issue":"12","key":"10.1016\/j.breast.2020.11.002_bib8","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.breast.2020.11.002_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","article-title":"A\u00a0randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy","volume":"113","author":"Yeo","year":"2009","journal-title":"Breast Canc Res Treat"},{"issue":"20","key":"10.1016\/j.breast.2020.11.002_bib10","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2014.55.3503","article-title":"Aprepitant versus dexamethasone to prevent delayed emesis after chemotherapy","volume":"32","author":"Ng","year":"2014","journal-title":"J\u00a0Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.breast.2020.11.002_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.29_suppl.176","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): alliance A221301, a randomized, double-blind, placebo-controlled trial","author":"Navari","year":"2015","journal-title":"American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.breast.2020.11.002_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-015-3669-8","article-title":"Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting","volume":"155","author":"Ng","year":"2016","journal-title":"Breast Canc Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2020.11.002_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ctrv.2015.09.007","article-title":"Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making","volume":"41","author":"Hutton","year":"2015","journal-title":"Canc Treat Rev"},{"issue":"11","key":"10.1016\/j.breast.2020.11.002_bib14","first-page":"3341","article-title":"Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients\u2019 experience","volume":"23","author":"Hernandez Torres","year":"2015","journal-title":"Support Care Canc: official journal of the multinational association of supportive care in cancer"},{"issue":"6","key":"10.1016\/j.breast.2020.11.002_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2020.11.002_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician\u2019s choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA oncology"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib17","first-page":"1563","article-title":"Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors","volume":"24","author":"Dranitsaris","year":"2016","journal-title":"Support Care Canc: official journal of the multinational association of supportive care in cancer"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib18","first-page":"863","article-title":"Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?","volume":"22","author":"Dranitsaris","year":"2014","journal-title":"Support Care Canc: official journal of the multinational association of supportive care in cancer"},{"issue":"6","key":"10.1016\/j.breast.2020.11.002_bib19","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.3747\/co.19.1074","article-title":"Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting","volume":"19","author":"Bouganim","year":"2012","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.breast.2020.11.002_bib20","first-page":"1655","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Canc: official journal of the multinational association of supportive care in cancer"},{"issue":"3","key":"10.1016\/j.breast.2020.11.002_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"10","key":"10.1016\/j.breast.2020.11.002_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jjco\/hyy114","volume":"48","author":"Hashimoto","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.breast.2020.11.002_bib23","author":"Bc Cancer Agency"},{"key":"10.1016\/j.breast.2020.11.002_bib24","author":"National Comprehensive Cancer Network"},{"issue":"28","key":"10.1016\/j.breast.2020.11.002_bib25","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2020.11.002_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1200\/JGO.2016.006023","article-title":"Survey of implementation of antiemetic prescription standards in Indian oncology practices and its adherence to the American society of clinical oncology antiemetic clinical guideline","volume":"3","author":"Patil","year":"2017","journal-title":"Journal of global oncology"},{"key":"10.1016\/j.breast.2020.11.002_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.breast.2020.11.002_bib29","author":"Eli Lilly Canada Inc"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib30","first-page":"W1","article-title":"Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting","volume":"7","author":"Dranitsaris","year":"2009","journal-title":"J\u00a0Support Oncol"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib31","first-page":"W9","article-title":"Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II. Delayed nausea and vomiting","volume":"7","author":"Petrella","year":"2009","journal-title":"J\u00a0Support Oncol"},{"issue":"1","key":"10.1016\/j.breast.2020.11.002_bib32","first-page":"14","article-title":"Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting","volume":"11","author":"Dranitsaris","year":"2013","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.breast.2020.11.002_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"A\u00a0randomized trial comparing risk model guided antiemetic prophylaxis to physician\u2019s choice in patients receiving chemotherapy for early stage breast cancer","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA oncology"},{"key":"10.1016\/j.breast.2020.11.002_bib34","article-title":"Validation of a 5-day recall version of the functional living index-emesis (FLIE) quality-of-life questionnaire for chemotherapy-induced emesis","author":"Martin","year":"2000","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.breast.2020.11.002_bib35","first-page":"35","article-title":"Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy","volume":"4","author":"Decker","year":"2006","journal-title":"J\u00a0Support Oncol"},{"issue":"8","key":"10.1016\/j.breast.2020.11.002_bib36","first-page":"522","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall","volume":"11","author":"Martin","year":"2003","journal-title":"Support Care Canc: official journal of the multinational association of supportive care in cancer"},{"issue":"3","key":"10.1016\/j.breast.2020.11.002_bib37","article-title":"Common terminology criteria for adverse events (CTCAE) version 4.0","volume":"4","author":"Health UDo","year":"2009","journal-title":"National Institutes of Health, National Cancer Institute"},{"issue":"4","key":"10.1016\/j.breast.2020.11.002_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A\u00a0sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"7","key":"10.1016\/j.breast.2020.11.002_bib39","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bcp.13242","article-title":"Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis","volume":"83","author":"Yang","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.breast.2020.11.002_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620302083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620302083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:57Z","timestamp":1760777037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977620302083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S0960977620302083"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.11.002","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}